Skip to search formSkip to main contentSkip to account menu

ribociclib

Known as: 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

AminopyridinesPurines

Narrower (1)

LEE011
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Review
2019
Review
2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Review
2019
Review
2019
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
BackgroundSeveral trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor… 
Highly Cited
2018
Highly Cited
2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
Review
2018
Review
2018
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Cell cycle dysregulation is a hallmark of all cancers, resulting in uncontrolled proliferation. Cyclin dependent kinases (CDKs… 
Review
2018
Review
2018
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
Endocrine therapy is recommended for patients with hormone receptor-positive (HR+) advanced and metastatic breast cancer without… 
Review
2017
Review
2017
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
The cyclin D–cyclin-dependent kinase (CDK) 4/6–p16–retinoblastoma (Rb) pathway is commonly disrupted in cancer, leading to… 
Highly Cited
2017
Highly Cited
2017
Ribociclib: First Global Approval
Ribociclib is an oral, small-molecule inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis… 
Highly Cited
2017
Highly Cited
2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
PurposeDetermine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2− advanced… 
Review
2016
Review
2016
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)